Samsung BioLogics Co Ltd

207940: XKRX (KOR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|^<>X#LOCK|Ym#VLOCK|L%W@F<

Samsung Bio Earnings: 2026 Guidance Reiterated; PolyPeptide Acquisition Another Driver

Samsung Biologics' second-quarter revenue grew 30% year on year to KRW 1.32 trillion, driven by full utilization of its plants. It also announced the acquisition of PolyPeptide, expected to close by year-end. Operating margin fell 270 basis points due to greater depreciation costs.

Sponsor Center